Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.
about
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesSurvival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphomaAllogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Biosimilars and the extrapolation of indications for inflammatory conditions.Biosimilar biologic drugs: a new frontier in medical care.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsBiosimilars: Key regulatory considerations and similarity assessment tools.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.An Extension Study of PF-05280586, a Potential Rituximab Biosimilar, versus Rituximab in Subjects with Active Rheumatoid Arthritis.Biosimilars Have Arrived: Rituximab.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaAccess to innovative cancer medicines in a middle-income country - the case of Mexico
P2860
Q33621041-EB8565CF-3BCE-44ED-BBD3-A9FD814E1731Q33665611-B92BC4B4-054B-4251-B7C2-B742A96B6B43Q35586706-A9258068-3417-47AA-BC8A-2D50394639A2Q36928725-EB010CC1-7F61-498F-8F70-4220B8F8D438Q37731321-90CBCDA4-89A0-4A8A-B9D6-0F2C4AA0E760Q38394272-09DE970D-267F-4563-904D-8BD3F4AF1F9CQ38643555-2BE35763-5B29-4B9B-BA6F-89C70A17A1B1Q38647397-6407CEA4-6F9A-41F1-A521-65A797D3656BQ38686396-34F47C17-E056-444E-BB18-ACA80A407BF3Q38932150-91CFB4B2-81E0-49B8-9C4A-93CC103979C4Q39200937-95D76EB7-C210-4688-8C6E-61C094340984Q42370596-24ABCA76-1799-464F-A530-B53FED831447Q46729332-10493B99-D5E0-4E92-9058-A67B82B4F861Q47796704-61AEA436-DCFC-4374-B2C9-E0E70FBA620AQ52801688-E600A7AA-2770-4814-B30B-2E315A4D88C7Q55105693-10C5D16F-4590-4C36-A8B5-CEE822164B31Q57173064-A7E666D9-FDF9-48FE-8423-2533B5C5A3FAQ58568145-7DBDB2A3-B4CB-4F6F-AB0B-4C1F01D4D56C
P2860
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@ast
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@en
type
label
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@ast
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@en
prefLabel
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@ast
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@en
P2093
P2860
P356
P1433
P1476
Barriers to the Access and Use ...... Leukemia: A Physician Survey.
@en
P2093
Archana Maini
Ira Jacobs
William H Baer Ii
P2860
P304
P356
10.3390/PH7050530
P577
2014-05-07T00:00:00Z